GLP's ⏱ Half-life: Approximately 168 hours (7 days) due to albumin binding via the C18 fatty diacid side chain and DPP-4 resistance. This enables once-weekly subcutaneous administration in research protocols. Steady state is reached after 4-5 weeks of weekly dosing.

Semaglutide

Semaglutide (GLP-1 Receptor Agonist)

Buy from $89.99 →
Half-Life
Approximately 168 hours (7 days) due to albumin binding via the C18 fatty diacid side chain and DPP-4 resistance. This enables once-weekly subcutaneous administration in research protocols. Steady state is reached after 4-5 weeks of weekly dosing.
Mol. Weight
4113.58 g/mol

What is Semaglutide?

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that represents a significant advancement in metabolic peptide research. Originally developed for glycemic control research, it has become one of the most extensively studied peptides in metabolic science.

The compound mimics the incretin hormone GLP-1, which is naturally released after eating and plays a central role in glucose metabolism, insulin secretion, and appetite regulation. Through strategic structural modifications, semaglutide achieves dramatically extended duration of action compared to native GLP-1.

Research Applications

Major research and clinical trial areas:

  • Glycemic regulation: SUSTAIN trial program (types 1-10) demonstrating HbA1c reduction
  • Body composition: STEP trial program examining weight management at higher doses
  • Cardiovascular: SELECT trial showing MACE reduction independent of glycemic effects
  • Hepatic: NASH/MAFLD models showing liver fat reduction and fibrosis improvement
  • Renal: FLOW trial examining kidney outcome benefits
  • Neurological: Early research into neurodegenerative disease models

Dosage Information (Research Use)

Published clinical research has utilized a titration approach to minimize GI-related observations:

  • Glycemic research doses: Starting 0.25 mg/week, titrated to 0.5 mg, then 1.0 mg weekly
  • Higher-dose research: Starting 0.25 mg/week, titrated through 0.5, 1.0, 1.7, to 2.4 mg weekly
  • Titration interval: 4 weeks at each dose level before escalation
  • Administration: Once weekly, subcutaneous

Use the PeptideBible GLP-1 Dose Plotter to visualize titration schedules.

Research compound only. Consult published literature for protocol details.

Reconstitution & Handling

Semaglutide requires careful reconstitution due to its lipophilic fatty acid chain:

  • Add BAC water slowly — semaglutide may take longer to dissolve than standard peptides
  • Gently roll the vial between palms — avoid shaking or vortexing
  • Solution should be clear and colorless; discard if cloudy
  • Protect from light during storage

Half-Life & Pharmacokinetics

Approximately 168 hours (7 days) due to albumin binding via the C18 fatty diacid side chain and DPP-4 resistance. This enables once-weekly subcutaneous administration in research protocols. Steady state is reached after 4-5 weeks of weekly dosing.

Reported Observations in Literature

Published clinical trial data reports:

  • Gastrointestinal effects are the most common observations: nausea, vomiting, diarrhea, constipation — typically transient and dose-dependent
  • Titration approach significantly reduces GI-related observations
  • Injection site reactions reported in some subjects
  • Published data notes associations with pancreatitis, gallbladder events, and thyroid C-cell observations in animal models

Key Research References

  • Marso SP, et al. “Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.” N Engl J Med. 2016 (SUSTAIN-6)
  • Wilding JPH, et al. “Once-Weekly Semaglutide in Adults with Overweight or Obesity.” N Engl J Med. 2021 (STEP 1)
  • Lincoff AM, et al. “Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.” N Engl J Med. 2023 (SELECT)

How Semaglutide Works

Semaglutide is a modified analog of human GLP-1 (glucagon-like peptide-1) with 94% structural homology to the native hormone. Key modifications include an amino acid substitution at position 8 (Aib) for DPP-4 resistance and acylation with a C18 fatty diacid chain that enables albumin binding. These modifications extend the half-life from 2 minutes (native GLP-1) to approximately 7 days, enabling once-weekly administration. It activates GLP-1 receptors in the pancreas (insulin secretion), brain (appetite regulation via hypothalamic signaling), and GI tract (gastric emptying delay).

Research Findings

Supported by the SUSTAIN, PIONEER, STEP, and SELECT clinical trial programs — among the most extensive datasets for any peptide compound. Research demonstrates dose-dependent effects on glycemic control and body composition. Brain penetrance data shows direct hypothalamic receptor activation, distinguishing it from peripherally-restricted GLP-1 agonists. Cardiovascular outcome data from SELECT trial showed reduction in major adverse cardiovascular events.

Dosage & Administration

Published clinical research has utilized a titration approach to minimize GI-related observations:

  • Glycemic research doses: Starting 0.25 mg/week, titrated to 0.5 mg, then 1.0 mg weekly
  • Higher-dose research: Starting 0.25 mg/week, titrated through 0.5, 1.0, 1.7, to 2.4 mg weekly
  • Titration interval: 4 weeks at each dose level before escalation
  • Administration: Once weekly, subcutaneous

Use the PeptideBible GLP-1 Dose Plotter to visualize titration schedules.

Research compound only. Consult published literature for protocol details.

Safety & Side Effects

Published clinical trial data reports:

  • Gastrointestinal effects are the most common observations: nausea, vomiting, diarrhea, constipation — typically transient and dose-dependent
  • Titration approach significantly reduces GI-related observations
  • Injection site reactions reported in some subjects
  • Published data notes associations with pancreatitis, gallbladder events, and thyroid C-cell observations in animal models
Important: All safety information is derived from published research, primarily animal studies. No controlled human clinical trial data exists unless explicitly noted. This compound is sold for research purposes only.

Quick Facts

Sequence Modified GLP-1 (7-37) analog with C18 fatty acid chain
Molecular Weight 4113.58 g/mol
Half-Life Approximately 168 hours (7 days) due to albumin binding via the C18 fatty diacid side chain and DPP-4 resistance. This enables once-weekly subcutaneous administration in research protocols. Steady state is reached after 4-5 weeks of weekly dosing.
Available Sizes 3mg, 5mg, 10mg
Storage Lyophilized: -20°C. Reconstituted: 2-8°C, protect from light, use within 28 days.

Key Research References

  • Marso SP, et al. "Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes." N Engl J Med. 2016 (SUSTAIN-6)
  • Wilding JPH, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity." N Engl J Med. 2021 (STEP 1)
  • Lincoff AM, et al. "Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes." N Engl J Med. 2023 (SELECT)

Get Semaglutide from SourcePeptides

Third-party tested • Research-grade purity • Fast US shipping

Shop Now →

Related Peptides

View all →
Dulaglutide
GLP's
FDA-approved GLP-1 receptor agonist for type 2 diabetes and cardiovascular risk reduction, administered once weekly.
View Profile → Buy at SP →
Exenatide
GLP's
First GLP-1 receptor agonist approved for diabetes, derived from Gila monster venom, available in twice-daily and once-weekly formulations.
View Profile → Buy at SP →
Cagrilintide
GLP's
Long-acting amylin analog that suppresses appetite and enhances satiety, being developed as a complement to GLP-1 drugs for…
View Profile → Buy at SP →